Extracellular signal-regulated kinases modulate DNA damage response - A contributing factor to using MEK inhibitors in cancer therapy

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5476-5482

  Wei, F ^a,b,c   Yan, J ^a,b   Tang, D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c Institute of Women and Children's Health   (China)

Author keywords

ATM; ATR; Checkpoint activation; DNA damage response (DDR); ERK1 2 kinases

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; HYDROXYUREA; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAF PROTEIN; RAS PROTEIN; RDEA 119; SELUMETINIB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; COLON CANCER; DNA DAMAGE; HELA CELL; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 82255169231     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194388     Document Type: Article

References (105)

1. Zhou, B. B.; Elledge, S. J. The DNA damage response: putting checkpoints in perspective Nature 2000, 408, 433-439.
2. Sherr, C. J.; Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501-1512. (Pubitemid 29297917)
3. Bhattacharya, S.; Ray, R. M.; Johnson L, R. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal. 2009, 21(4), 509-522.
4. Peng, C. Y.; Graves, P. R.; Thoma, R. S.; Wu, Z.; Shaw, A. S.; Piwnica-Worms, H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277, 1501-1505. (Pubitemid 27449237)
5. Meloche, S.; Pouysségur, J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 2007, 26, 3227-3239. (Pubitemid 46763017)
6. Dent, P.; Yacoub, A.; Fisher, P. B.; Hagan, M. P.; Grant, S. MAPK pathways in radiation responses. Oncogene 2003, 22, 5885-5896. (Pubitemid 37176709)
7. Tang, D.; Wu, D.; Hirao, A.; Lahti, J. M.; Liu, L.; Mazza, B.; Kidd, V. J.; Mak, T. W.; Ingram, A. J. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 2002, 277, 12710-12717. (Pubitemid 34952631)
8. Golding, S. E.; Rosenberg, E.; Neill, S.; Dent, P.; Povirk, L. F.; Valerie, K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 2007, 67, 1046-53.
9. Yan, Y.; Black, C. P.; Cowan, K. H. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 2007, 26, 4689-4698. (Pubitemid 47067411)
10. Wei, F.; Xie, Y.; Tao, L.; Tang, D. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal. 2010, 22, 1783-1789.
11. Wei, F.; Xie, Y.; Lizh, H.; Tao, L.; Tang, D. ERK1 and ERK2 kinases activate hydroxyurea-induced S-phase checkpoint in MCF7 cells by mediating ATR activation. Cell Signal 2011, 23, 259-268.
12. Wang, X.; Martindale, J. L.; Holbrook, N. J. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000, 275, 39435-39443. (Pubitemid 32058968)
13. Wu, D.; Chen, B.; Parihar, K.; He, L.; Fan, C.; Zhang, J.; Liu, L.; Gillis, A.; Bruce, A.; Kapoor, A.; Tang, D. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 2006, 25, 1153-1164.
14. Lee, J. H.; Kim, K. T. Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death. J Cell Physiol. 2007, 210, 784-797.
15. Mogila, V.; Xia, F.; Li, W. X. An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila. Dev Cell 2006, 11, 575-582. (Pubitemid 44430898)
16. Dai, Y.; Chen, S.; Pei, X. Y.; Almenara, J. A.; Kramer, L. B.; Venditti, C. A.; Dent, P.; Grant, S. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008, 112, 2439-2449.
17. Nishioka, C.; Ikezo, e T.; Yang, J.; Yokoyama, A. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis 2009, 14, 1108-1120.
18. Cimprich, K. A.; Cortez, D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008, 9, 616-27. (Pubitemid 352032926)
19. Lempiäinen, H.; Halazonetis, T. D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28, 3067-3073.
20. Burrows, A. E.; Elledge, S. J. How AT R turns on: TopBP1 goes on ATRIP with ATR. Genes Dev. 2008, 22, 1416-1421. (Pubitemid 351793075)
21. Bakkenist, C. J.; Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421, 499-506. (Pubitemid 36168436)
22. So, S.; Davis, A. J.; Chen, D. J. Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. J Cell Biol. 2009, 187, 977-990.
23. Taylor, A. M., Groom, A., Byrd, P. J. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. Ataxia-telangiectasialike disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair 2004, 3, 1219-1225. (Pubitemid 38997965)
24. Lee, J, H.; Paull, T. T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308, 551-554. (Pubitemid 40570585)
25. Difilippantonio, S.; Celeste, A.; Fernandez-Capetillo, O.; Chen, H. T.; Reina San Martin, B.; Van Laethem, F.; Yang, Y. P.; Petukhova, G. V.; Eckhaus, M.; Feigenbaum, L.; Manova, K.; Kruhlak, M.; Camerini-Otero, R. D.; Sharan, S.; Nussenzweig, M.; Nussenzweig, A.. Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models. Nat Cell Biol. 2005, 7, 675-685. (Pubitemid 40975748)
26. Falck, J.; Coates, J.; Jackson, S. P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434, 605-611. (Pubitemid 40488547)
27. Lee, J. H.; Paull, T. T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007, 26, 7741-7748. (Pubitemid 350242454)
28. Lee, J. H.; Paull, T. T. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 2004, 304, 93-96. (Pubitemid 38451463)
29. Costanzo, V.; Shechter MD.; Lupardus, P. J.; Cimprich, K. A.; Gottesman, M.; Gautier, J. An ATR-and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol Cell 2003, 11, 203-213. (Pubitemid 36126601)
30. Zou, L.; Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003, 300, 1542-1548. (Pubitemid 36682880)
31. Cortez, D.; Guntuku, S.; Qin,. J.; Elledge, S. J ATR and ATRIP: partners in checkpoint signaling. Science 2001, 294, 1713-1716. (Pubitemid 33104841)
32. Edwards, R. J.; Bentley, N. J.; Carr, A. M. A Rad3-Rad26 complex responds to DNA damage independently of other checkpoint proteins. Nat Cell Biol. 1999, 1, 393-398. (Pubitemid 129502804)
33. Paciotti, V.; Clerici, M.; Lucchini, G.; Longhese, M. P. The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev. 2000, 14, 2046-2059. (Pubitemid 30637354)
34. Rouse, J.; Jackson, S. P. LCD1: an essential gene involved in checkpoint control and regulation of the MEC1 signalling pathway in Saccharomyces cerevisiae. EMBO J 2000, 19, 5801-5812.
35. Wakayama, T.; Kondo, T.; Ando, S.; Matsumoto, K.; Sugimoto K. Pie1, a protein interacting with Mec1, controls cell growth and checkpoint responses in Saccharomyces cerevisiae. Mol Cell Biol. 2001, 21, 755-764. (Pubitemid 32104724)
36. Uchiyama, M.; Galli, I.; Griffiths, D. J.; Wang, T. S. A novel mutant allele of Schizosaccharomyces pombe rad26 defective in monitoring S-phase progression to prevent premature mitosis. Mol Cell Biol. 1997, 17, 3103-3115. (Pubitemid 27215025)
37. Ball, H. L.; Myers, J. S.; Cortez, D.. ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation. Mol Biol Cell. 2005, 16, 2372-2381. (Pubitemid 40632219)
38. Ball, H. L.; Ehrhardt, M. R.; Mordes, D. A.; Glick, G. G.; Chazin. W. J.; Cortez. D. Function of a conserved checkpoint recruitment domain in ATRIP proteins. Mol Cell Biol. 2007, 27, 3367-77. (Pubitemid 46691119)
39. Kumagai, A.; Lee, J.; Yoo, H. Y.; Dunphy, W. G. TopBP1 activates the ATR-ATRI Pcomplex. Cell 2006, 124, 943-55.
40. Zou, L.; Liu, D.; Elledge, S. J. Replication protein A-mediated recruitment and activation of Rad17 complexes. Proc Natl Acad Sci U S A. 2003, 100, 13827-13832. (Pubitemid 37499151)
41. Bermudez, V. P.; Lindsey-Boltz, L. A.; Cesare. A. J.; Maniwa, Y.; Griffith, J. D.; Hurwitz, J.; Sancar, A. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc Natl Acad Sci U S A. 2003, 100, 1633-1638. (Pubitemid 36254499)
42. Parrilla-Castellar, E. R.; Arlander, S. J.; Karnitz, L. Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair 2004, 3, 1009-1014. (Pubitemid 38997943)
43. Lee, J.; Kumagai, A.; Dunphy, W. G. The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 with ATR. J Biol Chem. 2007, 282, 28036-28044. (Pubitemid 47529479)
44. Delacroix, S.; Wagner, J. M.; Kobayashi, M.; Yamamoto, K.; Karnitz, L. M. The Rad9-Hus1-Rad1 (9-1-1) clamp activate checkpoint signaling via TopBP1. Genes Dev. 2007, 21, 1472-1477. (Pubitemid 46955719)
45. Mordes, D. A.; Glick, G. G.; Zhao, R.; Cortez, D. TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev. 2008, 22, 1478-1489. (Pubitemid 351793082)
46. Mok, M. T.; Henderson, B. R. A comparison of BRCA1 nuclear localization with 14 DNA damage response proteins and domains: identification of specific differences between BRCA1 and 53BP1 at DNA damage-induced foci. Cell Signal. 2010, 22(1), 47-56.
47. Kumagai, A.; Dunphy, W. G. How cells activate ATR. Cell Cycle 2006, 5, 1265-1268. (Pubitemid 43894277)
48. Meyerson, M.; Enders, G. H.; Wu, C. L.; Su, L. K.; Gorka.. C.; Nelson. C. Harlow, E.; Tsai, L. H. A family of human cdc2-related protein kinases. EMBO J. 1992, 11, 2909-2917.
49. Johnson, N.; Cai, D.; Kennedy, R. D.; Pathania, S.; Arora, M.; Li, Y. C.; D'Andrea, A. D.; Parvin. J. D.; Shapiro, G. I. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell. 2009, 35, 327-339.
50. Johnson, N.; Shapiro, G. I. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets. 2010, 14, 1199-1212.
51. Bolderson, E.; Richard, D. J.; Zhou, B. B.; Khanna, K. K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009, 15, 6314-6320.
52. Lee, G.; Origanti, S.; White, L. S.; Sun, J.; Stappenbeck, T. S.; Piwnica-Worms. H. Contributions Made by CDC25 Phosphatases to Proliferation of Intestinal Epithelial Stem and Progenitor Cells. PLoS One. 2011, 6(1), e15561.
53. Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 2000, 51, 289-305.
54. Krepinsky, J.; Wu, D.; Ingram, A.; Scholey, J.; Tang. D. Developments in MEK1 inhibitors and their use in the treatment of disease. Expert Opin Ther Patents 2002, 12, 1795-1811. (Pubitemid 36054582)
55. Peyssonnaux, C.; Eychène, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93, 53-62. (Pubitemid 33040860)
56. Kolch, W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 2005, 6, 827-837. (Pubitemid 41568732)
57. Cowley, S.; Paterson, H.; Kemp, P.; Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994, 77, 841-852. (Pubitemid 24187682)
58. Chen, J. R.; Plotkin, L. I.; Aguirre, J. I.; Han, L.; Jilka, R. L.; Kousteni, S.; Bellido, T.; Manolagas, S. C. Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens. J. Biol. Chem. 2005, 280, 4632-4638. (Pubitemid 40288632)
59. Davis, R. J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 1993, 268, 14553-14556. (Pubitemid 23206581)
60. Sheridan, D. L.; Kong, Y.; Parker, S. A.; Dalby, K. N.; Turk, B. E. Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. J Biol Chem. 2008, 283, 19511-19520.
61. Sharrocks, A. D.; Yang, S. H.; Galanis, A. Docking domains and substratespecificity determination for MAP kinases. Trends Biochem Sci. 2000, 25, 448-453. (Pubitemid 30662413)
62. Jacobs, D.; Glossip, D.; Xing, H.; Muslin, A. J.; Kornfeld, K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev. 1999, 13, 163-175. (Pubitemid 29061947)
63. Razidlo, G. L.; Johnson, H. J.; Stoeger, S. M.; Cowan, K. H.; Bessho, T.; Lewis, R. E. KSR1 is required for cell cycle reinitiation following DNA damage. J Biol Chem. 2009, 284, 6705-6715.
64. Liu, J.; Mao, W.; Ding, B.; Liang, C. S. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol. 2008, 295, H1956-65.
65. Saegusa, J.; Hsu, D. K.; Liu, W.; Kuwabara, I.; Kuwabara, Y.; Yu, L.; Liu, F. T. Galectin-3 protects keratinocytes from UVB-induced apoptosis by enhancing AKT activation and suppressing ERK activation. J Invest Dermatol. 2008, 128, 2403-2411.
66. Lee, S. W.; Fang, L.; Igarashi, M.; Ouchi, T.; Lu, K. P.; Aaronson, S. A. Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 8302-8305. (Pubitemid 30639667)
67. Persons, D. L.; Yazlovitskaya, E. M.; Pelling, J. C. Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin. J. Biol. Chem. 2000, 275, 35778-35785.
68. So, H.; Kim, H.; Lee, J. H.; Park, C.; Kim, Y.; Kim, E.; Kim, J. K.; Yun, K. J. Lee, K. M.; Lee, H. Y.; Moon, S. K.; Lim, D. J.; Park. R. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol. 2007, 8, 338-355. (Pubitemid 47222431)
69. Hamdi, M.; Popeijus, H. E.; Carlotti, F.; Janssen, J. M.; van der Burgt, C.; Cornelissen-Steijger, P.; van de Water, B.; Hoeben, R. C.; Matsuo, K.; van Dam, H. ATF3 and Fra1 have opposite functions in JNK-and ERK-dependent DNA damage responses. DNA Repair 2008, 7, 487-496.
70. Yan, Y.; Spieker, R. S.; Kim, M.; Stoeger, S. M.; Cowan, K. H. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005, 24, 3285-3296. (Pubitemid 40695110)
71. Pippin, J. W.; Durvasula, R.; Petermann, A.; Hiromura, K.; Couser, W. G.; Shankland, S. J. DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest. 2003, 111, 877-885. (Pubitemid 37074963)
72. Sheridan, C.; Brumatti, G.; Elgendy, M.; Brunet, M.; Martin, S. J. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinumbased chemotherapeutic drugs. Oncogene 2010, 29, 6428-6241.
73. Watanabe, M.; Naraba, H.; Sakyo, T.; Kitagawa, T. DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. Mol Cancer Res. 2010, 8, 1547-1557.
74. Ahmed, K. M.; Nantajit, D.; Fan, M.; Murley, J. S.; Grdina, D. J.; Li, J. J. Coactivation of ATM/ERK/NF-kappaB in the low-dose radiation-induced radioadaptive response in human skin keratinocytes. Free Radic Biol Med. 2009, 46, 1543-1550.
75. Khalil, A.; Morgan, R. N.; Adams, B. R.; Golding, S. E.; Dever, S. M.; Rosenberg, E.; Povirk, L. F.; Valerie, K. ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks. Cell Cycle 2011, 10, 481-491.
76. Cortez, D. Unwind and slow down: checkpoint activation by helicase and polymerase uncoupling. Genes & Dev 2005, 19, 1007-1012. (Pubitemid 40632445)
77. Segurado M, Tercero JA. The S-phase checkpoint: targeting the replication fork. Biol Cell 101, 617-27, 2009.
78. Chen, Y.; Sanchez, Y. Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair 2004, 3, 1025-1032. (Pubitemid 38997944)
79. Tembe, V.; Henderson, B. R. Protein trafficking in response to DNA damage. Cell Signal. 2007, 19, 1113-1120. (Pubitemid 46561571)
80. Lee, C.; Smith, B. A.; Bandyopadhyay, K.; Gjerset, R. A. DNA damage disrupts the p14ARF-B23 (nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 2005, 65, 9834-9842. (Pubitemid 41541462)
81. Karmakar, P.; Bohr, V. A. Cellular dynamics and modulation of WRN protein is DNA damage specific. Mech Ageing Dev. 2005, 126, 1146-1158. (Pubitemid 41356514)
82. Liu, F. J.; Barchowsky, A.; Opresko, P. L. The Werner syndrome protein functions in repair of Cr (VI)-induced replication-associated DNA damage. Toxicol Sci. 2009, 110, 307-318.
83. Rancourt, A.; Satoh, M. S. Delocalization of nucleolar poly (ADP-ribose) polymerase-1 to the nucleoplasm and its novel link to cellular sensitivity to DNA damage. DNA Repair 2009, 28, 286-297.
84. Tulchin, N.; Chambon, M.; Juan, G.; Dikman, S.; Strauchen, J.; Ornstein, L.; Billack, B.; Woods, N. T.; Monteiro, A. N. BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. Am J Pathol. 2010, 176, 1203-1214.
85. Bernardi, R.; Scaglioni, P. P.; Bergmann, S.; Horn, H. F.; Vousden, K. H.; Pandolfi, P. P. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol. 2004, 6, 665-672. (Pubitemid 38960925)
86. Li, D. Q.; Ohshiro, K.; Khan, M. N.; Kumar, R. Requirement of MTA1 in ATR-mediated DNA damage checkpoint function. J Biol Chem. 2010, 285, 19802-19812.
87. Pao, W.; Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010, 10(11):760-774.
88. Helgason, G. V.; Karvela, M.; Holyoake, T. L. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011, Jun. 21. [Epub ahead of print]
89. Matallanas, D.; Crespo, P. New druggable targets in the Ras pathway? Curr Opin Mol Ther. 2010, 12(6), 674-683.
90. Garnett, M. J.; Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6(4), 313-319. (Pubitemid 39361432)
91. Montagut, C.; Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283(2), 125-134.
92. Young, A.; Lyons, J.; Miller, A. L.; Phan, V. T.; Alarcón. I. R.; McCormick. F. Ras signaling and therapies. Adv Cancer Res. 2009, 102, 1-17.
93. Chappell, W. H.; Steelman, L. S.; Long, J. M.; Kempf, R. C.; Abrams, S. L.; Franklin, R. A.; Bäsecke, J.; Stivala, F,; Donia. M.; Fagone, P.; Malaponte, G.; Mazzarino, M. C.; Nicoletti, F.; Libra, M.; Maksimovic-Ivanic, D.; Mijatovic, S.; Montalto, G.; Cervello, M.; Laidler, P.; Milella, M.; Tafuri, A,.; Bonati, A.; Evangelisti, C.; Cocco, L.; Martelli, A. M.; McCubrey, J. A. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2(3), 135-164.
94. Rinehart, J.; Adjei, A. A.; Lorusso, P. M.; Waterhouse, D.; Hecht, J. R.; Natale, R. B.; Hamid, O.; Varterasian, M.; Asbury, P.; Kaldjian, E. P.; Gulyas, S.; Mitchell, D. Y.; Herrera, R.; Sebolt-Leopold, J. S. Meyer, M. B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004, 22(22), 4456-4462. (Pubitemid 41185111)
95. Haura, E. B.; Ricart, A. D.; Larson, T. G.; Stella, P. J.; Bazhenova, L.; Miller, V. A.; Cohen, R. B.; Eisenberg, P. D.; Selaru, P.; Wilner, K. D.; Gadgeel, S. M. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010, 16(8), 2450-2457.
96. LoRusso, P. M.; Krishnamurthi, S. S.; Rinehart, J. J.; Nabell, L. M.; Malburg. L.; Chapman. P. B.; DePrimo, S. E.; Bentivegna, S.; Wilner, K. D.; Tan. W.; Ricart. A. D. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor D-0325901 in patients with advanced cancers. Clin Cancer Res. 2010, 16(6), 1924-1937.
97. Garber, K. Trial offers early test case for personalized medicine. J Natl Cancer Inst. 2009, 101(3), 136-138.
98. Dy, G. MEK/MAPK inhibitors. J Thorac Oncol. 2010, 5(12 Suppl 6), S474-475.
99. Solit, D. B.; Garraway, L. A.; Pratilas, C. A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J. M.; She, Y.; Osman, I.; Golub, T. R.; Sebolt-Leopold, J.; Sellers, W. R.; Rosen, N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439, 358-362. (Pubitemid 43128863)
100. Yoon, Y. K.; Kim, H. P.; Han, S. W.; Oh do, Y.; Im, S. A.; Bang, Y. J.; Kim, T. Y. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010, 49(4), 353-362.
101. Corcoran, R. B.; Settleman, J.; Engelman, J. A. Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. Oncotarget 2011, 2(4), 336-346.
102. Poulikakos, P. I.; Rosen, N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011, 19(1), 11-15.
103. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007, 1773(8), 1263-1284. (Pubitemid 47125967)
104. Ciccia, A.; Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol Cell 2010, 40, 179-204.
105. Chung, E. J.; Brown, A. P.; Asano, H.; Mandler, M.; Burgan, W. E.; Carter, D.; Camphausen, K.; Citrin, D. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009, 15(9), 3050-3057.